" class="no-js "lang="en-US"> Aileen Lai - Medtech Alert
Thursday, October 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Aileen Lai

Aileen Lai

About Aileen Lai

A global executive with consistent proven track records, Aileen Lai spent most part of her career in Healthcare and Life Science in bring technology and innovation towards improving care. Her vast experience across HIS, EMR, CMS, EHR, PHR and BI/DW built up extensive domain knowledge and deep understanding of challenges in healthcare industry.

During her previous portfolio as COO of iHealth Labs, she built a remote patient monitoring platform. HealthBeats is founded post management buy-out of the platform. HealthBeats is also the authorised global distributor of iHealth Labs and AndesFit’s globally approved and award winning IoT medical devices.

HealthBeats has been successfully deployed and at-scale across multiple healthcare settings (public, acute, primary and remote care), use-cases and diseases. With support and trust from our health providers and patients, HealthBeats posted positive cashflow in its 2nd year of operations and positive cashflow and profitability in its 3rd year of operations.

Related Story

Fundraising

 HealthBeats Raises US$3m Seed Funding Led By Heritas Capital And SEEDS Capital To Expand Remote Vitals Monitoring In Australia And Singapore | Pharmtech Focus

HealthBeats Raises US$3m Seed Funding Led By Heritas Capital And SEEDS Capital To Expand Remote Vitals Monitoring In Australia And Singapore

April 29 2022

HealthBeatsTM, a Singapore-based healthtech start-up with end-to-end remote vitals monitoring solution, today announced the close of […]